title: Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer.
abstract: We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by (18)F-FDG-PET/CT scan and a partial response according to RECIST criteria. This patient indicates that ROS1 translocations are not restricted to young age, female gender and low stage. Furthermore, this case illustrates exemplarily that crizotinib therapy is effective and manageable even as first-line treatment in elderly patients with comorbidities. Based on our findings, we recommend to include elderly patients with advanced pulmonary adenocarcinomas in molecular screening approaches for ROS1 translocations.
authors.affiliation: Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany; Department of Hematology and Medical Oncology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Tobias R
authors.initials: TR
authors.lastname: Overbeck
authors.affiliation: Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Schmitz
authors.affiliation: Department of Radiology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Engelke
authors.affiliation: Department of Radiology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Carsten-Oliver
authors.initials: CO
authors.lastname: Sahlmann
authors.affiliation: Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Sara
authors.initials: S
authors.lastname: Hugo
authors.affiliation: Institute of Pathology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Laura
authors.initials: L
authors.lastname: Kellner
authors.affiliation: Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany; Department of Hematology and Medical Oncology, University Hospital Göttingen, Göttingen, Germany.
authors.forename: Lorenz
authors.initials: L
authors.lastname: Trümper
authors.affiliation: Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany; Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany.
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Schildhaus
keywords: Fluorescence in situ hybridization; NSCLC; Precision medicine; ROS1 rearrangement